12/4
08:00 am
ndra
ENDRA’s TAEUS® Liver Matches MRI-PDFF Performance at Key Clinical Thresholds, Positioning Device for MASLD/MASH Trial Use
High
Report
ENDRA’s TAEUS® Liver Matches MRI-PDFF Performance at Key Clinical Thresholds, Positioning Device for MASLD/MASH Trial Use
11/20
08:00 am
ndra
ENDRA Feasibility Study Demonstrates TAEUS® Accurately Quantifies Liver Fat Fraction, a Key MASLD/MASH Biomarker
Medium
Report
ENDRA Feasibility Study Demonstrates TAEUS® Accurately Quantifies Liver Fat Fraction, a Key MASLD/MASH Biomarker
11/17
08:00 am
ndra
ENDRA Life Sciences Recaps Major Milestones and New Strategic Initiatives, Announces Third Quarter 2025 Financial Results
Medium
Report
ENDRA Life Sciences Recaps Major Milestones and New Strategic Initiatives, Announces Third Quarter 2025 Financial Results
11/13
08:00 am
ndra
ENDRA Life Sciences Commences Staking of HYPE Digital Asset Holdings, Reinforcing Long-Term Strategy with Anchorage Digital and ARCA
Medium
Report
ENDRA Life Sciences Commences Staking of HYPE Digital Asset Holdings, Reinforcing Long-Term Strategy with Anchorage Digital and ARCA
10/23
08:00 am
ndra
ENDRA Life Sciences Closes Up to $14.4 Million Private Placement and Launches Crypto Treasury Strategy with $3 Million in Initial HYPE Token Holdings
Medium
Report
ENDRA Life Sciences Closes Up to $14.4 Million Private Placement and Launches Crypto Treasury Strategy with $3 Million in Initial HYPE Token Holdings
10/13
08:00 am
ndra
ENDRA Life Sciences Announces At-Market Private Placement of Up to $14.4 Million to Launch Digital Asset Treasury Strategy Managed by Leading Crypto Asset Manager Arca
Medium
Report
ENDRA Life Sciences Announces At-Market Private Placement of Up to $14.4 Million to Launch Digital Asset Treasury Strategy Managed by Leading Crypto Asset Manager Arca
10/3
03:35 pm
ndra
ENDRA Life Sciences (NASDAQ:NDRA) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
ENDRA Life Sciences (NASDAQ:NDRA) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
9/22
08:08 am
ndra
ENDRA Life Sciences (NASDAQ:NDRA) had its price target lowered by analysts at Ascendiant Capital Markets from $46.00 to $38.00. They now have a "buy" rating on the stock.
Low
Report
ENDRA Life Sciences (NASDAQ:NDRA) had its price target lowered by analysts at Ascendiant Capital Markets from $46.00 to $38.00. They now have a "buy" rating on the stock.